For Healthcare Professionals

Tislelizumab in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma

clipboard-pencil

About the study

The primary objective of the study is to evaluate the efficacy of tislelizumab in participants with relapsed/refractory classical Hodgkin lymphoma, as measured by the overall response rate per the Lugano Classification, and as determined by the investigator.
user-3

Who can take part

You may be eligible to participate in the study if you meet the following criteria:

INCLUSION CRITERIA

  1. Histologically confirmed diagnosis of relapsed or refractory cHL
  2. Relapsed cHL (disease progression after PR or CR to the most recent therapy) or refractory cHL (failure to achieve PR or CR to most recent therapy). Participants will be allocated to one of two cohorts based on the following criteria: Cohort 1: Relapsed or refractory to prior autologous hematopoietic stem cell transplant (HSCT)
  3. Has failed to achieve a response or progressed after autologous HSCT
  4. Is not a candidate for additional autologous or allogeneic HSCT Cohort 2: Relapsed or refractory to salvage chemotherapy, and has not received prior autologous or allogeneic HSCT
  5. Is not a candidate for autologous or allogeneic HSCT
  6. Has received at least 1 prior systemic regimen for cHL
  7. Measurable disease defined as ≥ 1 2-[18F] fluoro-2-deoxy-D-glucose (FDG)-avid nodal lesion that is > 1.5 cm in the longest diameter, or ≥ 1 FDG-avid extra-nodal lesion (eg, hepatic nodules) that is > 1 cm in the longest diameter
  8. Eastern Cancer Oncology Group (ECOG) performance status of 0 or 1 Key

EXCLUSION CRITERIA

  1. Nodular lymphocyte-predominant Hodgkin lymphoma or gray zone lymphoma
  2. Prior allogeneic hematopoietic stem cell transplantation
  3. Prior therapy targeting PD-1 , PD-L1,PD-L2, or CTLA-4 (cytotoxic T-lymphocyte-associated protein 4) pathways
  4. Active autoimmune disease or history of autoimmune disease that may relapse NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.
pin location

Study Locations

Enter your ZIP code/Postal code/PIN code to locate study sites near you:

How to Apply


Contact the study center to learn if this study is a good match for you.
Phone iconCall 1-877-828-5568Email iconEmail Study Center

Study’s details


Contition

Classical Hodgkin Lymphoma

Age

18+

Phase

Phase 2

Participants needed

46

Est. Completion Date

Sep 2023

Treatment type

Interventional


Sponsor

BeiGene

ClinicalTrials.gov identifier

NCT04318080

Study number

BGB-A317-210

Understanding Clinical Trials


Get answers to your questions about clinical trials.What is a clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?
Vector

Interested?

Sign up to save your favorites, 
receive newsletters, resources, and alerts 
about clinical trials related to your conditions of interest.